Position
Squarepoint Ops LLC in Relmada Therapeutics, Inc.
Back to the book · All holders of RLMD
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $135.1K$4.83 → $6.96
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 138.2K | $667.7K | — | — | — | 0.0% |
| Q1 2026 | 63.4K | $441.4K | $6.96 | $135.1K | −$361.3K | 0.0% |